MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The first results of Anti-Vascular Endothelial Growth Factor (VEGF) therapy were very
promising and superior to established therapies. Three different substances (all of them
applied intravitreally) are available, but comparative studies have not yet been conducted.
In this pilot study, the safety (number of adverse events) and efficacy (distance acuity
testing retinal thickness measurement) of Avastin and Macugen applied as monotherapy will be
compared to a combined treatment of Avastin followed by Macugen used for retreatment.
At least equal results of the combined therapy are expected.
Phase:
Phase 2
Details
Lead Sponsor:
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery